Phase 1 data support plans to move ... Nine patients (9%) experienced fatal adverse reactions which included infections (sepsis, pneumonia, peritonitis), ascites, pulmonary embolism, acute respiratory ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

"This decision not only validates the strength of the Phase 3 PROTECT ... The most common adverse reactions (?5%) are hyperkalemia, hypotension (including orthostatic hypotension), peripheral edema, ...

The FDA approval of Monjuvi was based on data from the MorphoSys-sponsored phase ... reactions, serious or severe myelosuppression (including neutropenia (50%), thrombocytopenia (18%), and anemia ...

In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

“We think it’s safe to say that the acute phase of the selloff is over,” said Bespoke Investment Group, in a note after the U.S. stock market closed Tuesday. The firm cited a third straight ...

The most common adverse reactions reported during the trial were upper respiratory tract infections, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, and nausea.

The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update.